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Introduction: Tumor necrosis factor related-apoptosis-inducing ligand 
(TRAIL) is a powerful and selective activator of apoptosis in many cancer 
cells. We aim to investigate the expression and significance of TRAIL death 
receptor DR4 and DR5 in pancreatic cancer (PC) tissues. 
 
Method: Twenty-eight histologically verified samples of PC tissue were 
collected between 2018 and 2019. TRAIL death receptor expression 
profiles were determined by immunohistochemistry.  
 
Result: Death receptor DR4 and DR5 were expressed in the PC tissue and 
the adjacent non-cancerous pancreatic tissues, the expression of DR4 and 
DR5 in the PC tissue was significantly higher than that of the adjacent non-
cancerous pancreatic tissues (p<0.05). Additionally, in both the tissue 
group, the expression of DR4 was significantly stronger than the DR5 
(p<0.05). To assess the relationship between DR4 and DR5 expression, 
differentiation, and tumor staging of PC, the result reveals that the 
expression of DR4 and DR5 was significantly higher in stage I tumors than 
the stage II, III, IV tumors (p<0.05). In contrast, the expression of DR4 and 
DR5 was decreased with a decrease in the degree of differentiation of 
tumors. However, the difference was not statistically significant. 
 
Conclusion: The membrane expression of TRAIL death receptor DR4 and 
DR5 is greater in PC than in the adjacent non-cancerous pancreatic tissues. 
Furthermore, increased membrane expression of TRAIL death receptor 
DR4 and DR5 in stage I PC and well-differentiated PC may predict the 
prognosis and feasibility of using TRAIL gene therapy as a treatment option 
for early PC.   
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Pancreatic cancer (PC) is deadly cancer and the 
fourth leading cause of cancer death in the 
United States.1 Even with the multidisciplinary 
treatment approach the outcome of patients 
with PC has been unsatisfactory with a five-
year survival of <5%.2-9  
 
The advancement of the tumor is associated 
with the dysfunction of apoptosis.10-13 
Recently, tumor necrosis factor related-
apoptosis-inducing ligand (TRAIL), a type II 
membrane protein, is a powerful and selective 
activator of apoptosis in many cancer cells.14-18 
It interacts with five different death receptors: 
TRAIL-R1 (DR4), TRAIL-R2 (DR5), TRAIL-R3 
(DcR1), TRAIL-R4 (DcR2), and osteoprotegerin. 
Death receptors DR4 and DR5 are membrane-
bound receptors and contains the death 
domain in its intracellular portion that signals 
for apoptosis. In contrast, DcR1, DcR2, and 
osteoprotegerin are soluble receptors and do 
not contain a death domain; thus, they are 
unable to transmit the apoptotic signal.19-21 
The expression of TRAIL and its receptors has 
widely been studied in normal and cancerous 
tissues.22-27 Moreover, studies have also 
revealed that loss of TRAIL receptor expression 
correspond with bad prognosis and tumor 
recurrence.27-33 
 
We aim to assess the membrane expression of 
DR4 and DR5 in PC tissues and adjacent non-
cancerous pancreatic tissue by 





Tissue samples were obtained from patients 
already diagnosed with PC, who underwent 
pancreatic resection between 2018 to 2019 at 
Lihuili Hospital, Ningbo, China. Clinical and 
pathological characteristics were obtained 
from the medical records. Original pathology 
reports, including age, histological tumor type 
and grade, tumor size, and lymph node status 
were analyzed. Freshly removed tissue 
samples were immediately fixed in 
paraformaldehyde solution for 12-24 hours 
and paraffin-embedded for IHC. The study was 
approved by the Human Subject Committee of 
the Lihuili Hospital and has been performed in 
accordance with the ethical standards as laid 
down in the 1964 Declaration of Helsinki and 
its later amendments or comparable ethical 
standards. Consent was obtained from all 
individual participants included in the study. 
  
Immunohistochemistry (IHC): Tissue sections 
(5 μm thickness) were prepared, 
deparaffinized in xylene, and hydrated using 
an ethanol gradient. Antigen retrieval and IHC 
were performed. Antigen retrieval was 
performed for both DR4 and DR5 by 
microwave treatment of the slides at 1000 W 
in 1 L distilled water with phosphate-buffered 
saline (PBS) and heated to a boiling point, the 
power was cut off and the process was 
repeated after 10 minutes of interval, the slide 
was then rinsed with PBS twice after cooling. 
Endogenous peroxidase was blocked with 0.3% 
H2O2 in PBS solution [6.4 mM Na2HPO4H2O, 1.5 
mM KH2PO4, 0.14 M NaCl, and 2.7 mM KCl (pH 
7.8)] for 10 min at room temperature, and was 
rinsed twice with PBS, followed by incubation 
with primary antibody (DR4 and DR5 antibody) 
diluted with PBS (1:100) for 1 hour at 37°C or 
4°C overnight and was rinsed in PBS (3×2 min). 
After washing with PBS, the slides were 
incubated with a 1:100 dilution of a 
biotinylated rabbit-antigoat antibody (DAKO) 
for 25 min and was rinsed in PBS (3×2 min), 
followed by the addition of a drop of A and B 
reagent (DAKO) into 1mL distilled water 
respectively， the solution was mixed and 
dropped to the sections. The microscope was 
used to observe the DAB chromogenic 
reaction, the chromogenic reaction was 
controlled on time by rinsing the slide with 
distilled water. Counterstaining was 
performed with hematoxylin for 2 min. The 
slide was further rinsed with distilled water, 
dried completely with a drier and mounted 
with natural gum, and covered with a slit. Thus, 
the slide was ready for microscopic 
examination. 
  
Immunohistochemical scoring of DR4 and DR5: 
Tissue sections were analyzed by a single 
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patient status or antibodies used. The 
calculation of the final immunohistochemical 
staining scores in pancreatic tissues included 
both intensity and marker distribution 
(percentage of the positively stained epithelial 
cells). The intensity of the pancreatic tissue 
staining was assessed as follows: 0, negative; 
1, weak; 2, moderate; and 3, strong. Moreover, 
marker distribution was calculated as 0, less 
than 10%; 1, 10% to 40%; 2, 40% to 70%; and 
3, more than 70% of the epithelial cells stained 
on the sections. Summing the scores of both 
the intensity and the marker distribution for a 
given patient resulted in the final 
immunostaining score.  
 
Statistical analyses were performed using SPSS 
18.0 statistical data processing software, the 
data were analysed by Non-parametric tests 
and the SEM is displayed as error bars for all 





A total of 28 PC tissue samples were obtained 
from patients already diagnosed with PC. The 
median age of the patients was 63 years. There 
were 5 cases of well-differentiated, 12 cases of 
medium differentiated, and 11 cases of poorly 
differentiated PC in which 7 cases were in 
stage I (cancer confined to the pancreas), and 
the rest 21 cases in stage II, stage III and stage 
IV in combined (cancer invaded to surrounding 
tissue other than the pancreas). 
 
Expression of DR4 and DR5 in the pancreatic 
cancer tissue and the adjacent non-cancerous 
pancreatic tissues: DR4 and DR5 were 
expressed in the PC tissue and the adjacent 
non-cancerous pancreatic tissues, Figure 1A, B, 
C, D.  The expression of DR4 and DR5 in the PC 
tissue was significantly higher than that of the 
adjacent non-cancerous pancreatic tissues (p 
<0.05), Figure 2. In both the tissue group, the 
expression of DR4 was significantly higher than 
the DR5 (P <0.05).  
 
Relationship between DR4 and DR5 
expression, differentiation, and staging of PC: 
The results for the relationship between DR4 
and DR5 expression, differentiation and tumor 
staging of PC shows that the expression of DR4 
and DR5 was significantly higher in non-lymph 
node metastasis (stage I) tumors than the 
lymph node metastasis (stage II, III, IV) tumors 
(p<0.05), Figure 3. In contrast, expression of 
DR4 and DR5 was decreased with a decrease in 
degree of differentiation of tumors, Figure 4, 
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Figure 1C      Figure 1D 
 
Figure 1A-D . Expression of DR4 and DR5 in PC tissue and adjacent non-cancerous tissue  
 
A. Positive membrane expression of DR4 in PC; B. Positive membrane expression of DR4 in adjacent non-cancerous 
pancreatic tissues; C. Positive membrane expression of DR5 in PC;  D. Positive membrane expression of DR4 in adjacent 




Figure 2. Qualitative analysis of immunohistochemical expression of DR4 and DR5 in PC tissue versus 
adjacent non-cancerous pancreatic tissue.  
Note: Immunohistochemical scoring (mean±SEM) was performed as described in the materials and methods using the 
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Figure 3. Qualitative analysis of immunohistochemical expression (mean±SEM) of DR4 and DR5 in non-
lymph node metastasis (Stage I) and lymph node metastasis (Stage II, III, and IV) PC.  




Figure 4. Qualitative analysis of immunohistochemical expression (mean±SEM) of DR4 and DR5 in well-
differentiated, medium differentiated, and poorly differentiated PC.  




Pancreatic cancer is one of the most 
devastating malignant cancer and the fourth 
leading cause of cancer death.1 Very little 
progress has been achieved in the treatment of 
PC in the last 25 years, possibly because PC 
harboring a complex network of mutated 
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TRAIL as a powerful and selective activator of 
apoptosis in many cancer cells with minimal 
effect on normal cells and as a potent cancer 
preventive negotiator has attracted 
researchers to use the TRAIL gene as an anti-
cancer therapy in the clinical practice.14-18 The 
TRIAL binds to DR4 and DR5 receptors and 
initiates the formation of a protein complex 
called the death-inducing signaling complex 
(DISC), which further is responsible to induce 
apoptosis through a chain of steps.35 However, 
decoy receptors present on the cancer cells 
can inhibit the apoptosis induced by TRAIL.34 In 
past years, many studies have successfully 
reported potential clinical use of rhTRAIL in 
different cancers.29-32 Nonetheless, many areas 
of TRAIL as an anti-cancer therapy is still yet to 
be explored.  
 
Our study confirmed that TRAIL death 
receptors DR4 and DR5 are expressed in both 
the PC tissue and the adjacent non-cancerous 
pancreatic tissues. Encouragingly, several 
previous studies have reported the expression 
of DR4 and DR5 in the cell membrane, 
cytoplasm, nucleus, normal and cancerous 
cells.22-27,36 Besides, our study also found that 
the expression of DR4 and DR5 was 
significantly higher in stage I tumors than that 
of stage II, III, or IV tumors. This finding was 
consistent with previous studies, where it has 
revealed that the loss of DR4 and DR5 
expression in cancerous tissue leads to poor 
prognosis, recurrence, and progression of 
cancer.28,37 Furthermore, the loss in expression 
of TRAIL death receptor (DR4 and DR5) in late 
stages of PC has been associated with TRAIL 
resistance.33,38 A recent study revealed that 
some PC cells use DR4 to induce cell death, 
whereas other PC cells such as AsPC-1 and 
BxPC-3 cells trigger apoptosis through DR5.39 
Another research demonstrated that 
drozitumab, a human agonistic monoclonal 
antibody binds with DR5 and selectively 
eliminates cancer stem cells in patient-derived 
pancreatic tumor xenografts (PDX) model, 
resulting in regression of PC and long-term 
tumor control.40 Thus, the TRAIL death 
receptor expression in PC is an important 
target for the success of PC treatment. 
 
The limitation of this study is the small sample 
size and demands further prospective studies 
in larger populations to confirm these results 





The membrane expression of TRAIL death 
receptor DR4 and DR5 was greater in PC than 
the adjacent non-cancerous pancreatic tissues. 
The increased membrane expression of TRAIL 
death receptor DR4 and DR5 in stage I PC and 
well-differentiated PC may predict the 
prognosis and feasibility of using TRAIL gene 
therapy as a treatment option for early PC. The 
increased membrane expression of TRAIL 
death receptor DR4 and DR5 in stage I PC and 
well-differentiated PC may predict the 
prognosis and feasibility of using TRAIL gene 
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